Caspases and inflammasomes in metabolic inflammation

Immunology and Cell Biology

Volumn 92, Issue 4, 2014, Pages 304-313

  Skeldon, Alexander M ^a   Faraj, May ^b   Saleh, Maya ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Caspases; diabetes; inflammasome; metabolism; microbiota; obesity

Indexed keywords

CASPASE; CHOLESTEROL; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; CYTOKINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG TARGETING; HUMAN; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC REGULATION; METABOLISM; MICROFLORA; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASES; ENZYMOLOGY; IMMUNOLOGY;

MURINAE;

ANIMALS; CASPASES; CYTOKINES; DISEASE; HUMANS; IMMUNITY; INFLAMMASOMES; INFLAMMATION;

EID: 84899414605     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.5     Document Type: Review

References (95)

1. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
2. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
3. Suganami T, Tanaka M, Ogawa Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocr J 2012; 59: 849-857.
4. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart S tudy. Circulation 2007; 116: 1234-1241.
5. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377.
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
7. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784-2789.
8. Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol 2004; 82: 170-190.
9. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF. Acute en hancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999; 276: E1055-E1066.
10. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperins ulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993; 42: 833-842.
11. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
12. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005; 36: 232-240.
13. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454-462.
14. Saleh M. The machinery of Nod-like receptors: refining the paths to immunity and cell death. Immunol Rev 2011; 243: 235-246.
15. Schroder K, Tscho pp J. The inflammasomes. Cell 2010; 140: 821-832.
16. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T et al. Inflammasomemediated dysbiosis regulates progression of NA FLD and obesity. Nature 2012; 482: 179-185.
17. Im SS, Yousef L, Blaschitz C, Liu JZ, Edwards RA, Young SG et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab 2011; 13: 540-549.
18. Kayagaki N Warming S Lamkanfi M Vande Walle L Louie S Dong J et al. Noncanonical inflamma some activation targets caspase-11 Nature 2011 479 117-121.
19. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA et al. The inflammasome-mediated cas pase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010; 12: 593-605.
20. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011; 108: 15324-15329.
21. Wang H, Capell W, Yoon JH, Faubel S, Eckel R H. Obesity development in caspase-1-deficient mice. Int J Obes (Lond) 2013; 38: 152-155.
22. Kotas ME, Jurczak MJ, Annicelli C, Gillum MP, Cline GW, Shulman GI et al. Role of caspase-1 in regulation of triglyceride metabolism. Proc Natl Acad Sci USA 2013; 110: 4810-4815.
23. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
24. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
25. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249.
26. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesityassociated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
27. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ et al. NLRP6 inflammasome regulates coloni c microbial ecology and risk for colitis. Cell 2011; 145: 745-757.
28. Ubeda C, Lipuma L, Gobourne A, Viale A, Leiner I, Equinda M et al. Familial transmission rather than defective i nnate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med 2012; 209: 1445-1456.
29. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor. Science 2010; 328: 228-231.
30. van Diepen JA, Stienstra R, Vroegrijk IO, van den Berg SA, Salvatori D, Hooiveld GJ et al. Caspase-1 deficiency in mice reduces intestinal triglyceride absorption and hepatic triglyceride secretion. J Lipid Res 2013; 54: 448-456.
31. Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh M. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007; 282: 36321-36329.
32. Ahma dian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19: 557-566.
33. He F, Doucet JA, Stephens JM. Caspase-mediated degradation of PPARgamma proteins in adipocytes. Obesity (Silver Spring) 2008; 16: 1735-1741.
34. Guilherme A, Tesz GJ, Guntur KV, Czech MP. Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes. J Biol Chem 2009; 284: 17082-17091.
35. Chalkiadaki A, G uarente L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol 2012; 8: 287-296.
36. Chalkiadaki A, Guarente L. High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab 2012; 16: 180-188.
37. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ et al. Serine phosphorylation of insulin receptor substrate by inhibitor kappa B kinase complex. J Biol Chem2002 277 48115-48121.
38. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K et a l. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
39. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflamm atory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426.
40. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374.
41. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-1547.
42. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
43. Youm YH, Adijiang A, Vandanmagsar B, Burk D, Ravussin A, Dixit VD. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011; 152: 4039-4045.
44. Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocanna binoids mediates beta cell loss in type 2 diabetes. Nat Med 2013; 19: 1132-1140.
45. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-8632.
46. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 2004; 53: 1509-1516.
47. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996; 93: 7283-7288.
48. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA et al. Activation of th e NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
49. Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakaga wa Y, Igbaria A et al. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab 2012; 16: 250-264.
50. Oslowski CM, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M et al. Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab 2012; 16: 265-273.
51. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
52. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013; 13: 709-721.
53. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al. NLRP3 inflammas omes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
54. Rajamaki K, Lappalainen J, Oörni K, Välimäki E, Matikainen S, Kovanen PT et al. Ch olesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010; 5: e11765.
55. Kunjathoor VV, Febbraio M, Podrez EA, Mo ore KJ, Andersson L, Koehn S et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277: 49982-49988.
56. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11: 155-161.
57. Sheedy FJ Grebe A Rayner KJ Kalantari P Ramkhelawon B Carpenter SB et al. CD36 coordinates NLRP3 inflammasome activa tion by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation Nat Immunol 2013 14 812-820.
58. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
59. Menu P, Pellegrin M, Aubert JF, Bouzourene K, Tardivel A, Mazzolai L et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis 2011; 2: e137.
60. Usui F, Shirasuna K, Kimura H, Tatsumi K, Kawashima A, Karasawa T et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. B iochem Biophys Res Commun 2012; 425: 162-168.
61. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002; 5: 545-549.
62. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
63. Pal D, Dasgupt a S, Kundu R, Maitra S, Das G, Mukhopadhyay S et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279-1285.
64. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab 2012; 15: 585-594.
65. Koenen TB, Stienstra R, van Tits LJ, de Graaf J, Stalenhoef AF, Joosten LA et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes 2011; 60: 517-524.
66. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-232.
67. Sun S, Xia S, Ji Y, Kersten S, Qi L. The ATP-P2-7 signaling ax is is dispensable for obesity-associated inflammasome activation in adipose tissue. Diabetes 2012; 61: 1471-1478.
68. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-677.
69. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al. Silica crystal s and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847-856.
70. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
71. Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1betainduced insulin resistan ce in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148: 241-251.
72. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011; 60: 1688-1698.
73. Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM et al. Decreased fat mass in interleukin-1 receptor an tagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005; 54: 3503-3509.
74. Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 2003; 198: 877-888.
75. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ et al. Defic iency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12: 650-656.
76. Zorrilla EP, Sanchez-Alavez M, Sugama S, Brennan M, Fernandez R, Bartfai T et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA 2007; 104: 11097-11102.
77. Lindegaard B, Matthews VB, Brandt C, Hojman P, Allen TL, Estevez E et al. Interleukin-Activates Skeletal Muscle AMPK and Reduces Weight Gain and Insulin Resistance in Mice Diabetes 2013 62 3064-3074.
78. Moriwak i Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003; 52: 605-608.
79. Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic huma ns. Clin Immunol 2005; 117: 152-160.
80. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 1268-1273.
81. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol 2012; 13: 907-915.
82. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012; 15: 432-437.
83. Tannahill GM, Curtis AM, Adamik J, Palsson-McDerm ott EM, McGettrick AF, Goel G et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013; 496: 238-242.
84. Xiao H, Lu M, Lin TY, Chen Z, Chen G, Wang WC et al. Sterol regulatory element binding protein activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 2013; 128: 632-642.
85. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006; 126: 1135-1145.
86. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62: 194-204.
87. Goossens GH, Blaak EE, Theunissen R, Duijvestijn AM, Clément K, Tervaert JW et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in h umans. Mol Immunol 2012; 50: 142-149.
88. Esser N, L'homme L, De Roover A, Kohnen L, Scheen AJ, Moutschen M et al. Obesity phenotype is related to NLRP3 inflammasome activity and immu nological profile of visceral adipose tissue. Diabetologia 2013; 56: 2487-2497.
89. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antago nist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
90. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 recepto r antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
91. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H et al. Effects of gevok izumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662.
92. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 2012; 32: 203-227.
93. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C et al. Omega-3 fatty acids prevent inflammation and metabo lic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013; 38: 1154-1163.
94. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K et al. Glyburi de inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009; 187: 61-70.
95. Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the cirt and cantos trials Trans Am Clin Climatol Assoc 2013; 124: 174-190.